COVID-19 ‘cocktail’ therapy moves to clinical trial
A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.
The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…